# US 2026/0276657 A1 · Targets and methods of diagnosing, monitoring and treating frontotemporal dementia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0276657 A1
- Document ID: US20260276657A1
- Status: Published application
- Kind: A1
- Application number: 19/697,497
- Filed: 2026-06-03
- Published: 2026-09-17
- Earliest claimed: 2019-06-13
- Assignees: Arizona Board of Regents on behalf of Arizona State University
- Inventors: Michael Sierks; Stephanie Williams
- Web page: https://patentgrep.com/patent/US20260276657A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6857: {Antibody fragments}
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2800/30: Psychoses; Psychiatry
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are antibodies, antibody fragments, binding agents, and compositions that specifically recognize protein variant biomarkers associated with frontotemporal dementia, kits and methods of use, including diagnosing, monitoring and treating frontotemporal dementia.

## Claims

### Claim 1

A method of diagnosing a subject with frontotemporal dementia (FTD), the method comprising:
contacting a biological sample from a subject at risk or suspected of having FTD with a single-chain variable fragment (scFv) reactive with one or more oligomeric beta amyloid disease variants, wherein the scFv reactive with one or more oligomeric beta amyloid disease variants has a light chain complementary determining region (CDR) and heavy chain CDR combination selected from the group consisting of:
SEQ ID NOS: 21 (CDR-L1), 26 (CDR-L2), 43 (CDR-L3), 62 (CDR-H1), 66 (CDR-H2), and 85 (CDR-H3); and
SEQ ID NOS: 21 (CDR-L1), 27 (CDR-L2), 44 (CDR-L3), 61 (CDR-H1), 67 (CDR-H2), and 85 (CDR-H3); and
detecting binding between the scFvs and the biological sample, wherein the detection of binding between the scFv to the biological sample is indicative that the subject has or is likely to develop FTD.

### Claim 2 (depends on 1)

The method of claim 1, wherein the scFv reactive with one or more oligomeric beta amyloid disease variants has the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4.

### Claim 3 (depends on 1)

The method of claim 1, further comprising:
contacting the biological sample from the subject at risk or suspected of having FTD with one or more additional scFvs reactive with TAR DNA-binding protein 43 (TDP-43) disease variants, alpha-syn disease variants, or tau disease variants, wherein the one or more additional scFvs reactive with TDP-43 disease variants, alpha-syn disease variants, or tau disease variants has a light chain CDR and heavy chain CDR combination or a light chain CDR combination and truncated heavy chain selected from the group consisting of:
SEQ ID NOS: 21 (CDR-L1), 24 (CDR-L2), 41 (CDR-L3), 61 (CDR-H1), 64 (CDR-H2), and 83 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 24 (CDR-L2), 41 (CDR-L3), 101 (CDR-H1), 103 (CDR-H2), and 83 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 25 (CDR-L2), 42 (CDR-L3), 61 (CDR-H1), 65 (CDR-H2), and 84 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 28 (CDR-L2), 45 (CDR-L3), 61 (CDR-H1), 68 (CDR-H2), and 87 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 28 (CDR-L2), 45 (CDR-L3), 101 (CDR-H1), 106 (CDR-H2), and 87 (CDR-H3);
SEQ ID NOS: 22 (CDR-L1), 29 (CDR-L2), 46 (CDR-L3), 61 (CDR-H1), 69 (CDR-H2), and 88 (CDR-H3);
SEQ ID NOS: 22 (CDR-L1), 29 (CDR-L2), 46 (CDR-L3), 101 (CDR-H1), 107 (CDR-H2), and 88 (CDR-H3);
SEQ ID NOS: 23 (CDR-L1), 30 (CDR-L2), 47 (CDR-L3), 63 (CDR-H1), 70 (CDR-H2), and 89 (CDR-H3);
SEQ ID NOS: 23 (CDR-L1), 30 (CDR-L2), 47 (CDR-L3), 102 (CDR-H1), 108 (CDR-H2), and 89 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 32 (CDR-L2), and 49 (CDR-L3);
SEQ ID NOS: 21 (CDR-L1), 27 (CDR-L2), 50 (CDR-L3), 61 (CDR-H1), 72 (CDR-H2), and 91 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 26 (CDR-L2), 51 (CDR-L3), 61 (CDR-H1), 73 (CDR-H2), and 92 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 26 (CDR-L2), 51 (CDR-L3), 101 (CDR-H1), 110 (CDR-H2), and 92 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 33 (CDR-L2), 52 (CDR-L3), 61 (CDR-H1), and 74 (CDR-H2);
SEQ ID NOS: 21 (CDR-L1), 33 (CDR-L2), 52 (CDR-L3), 101 (CDR-H1), and 111 (CDR-H2);
SEQ ID NOS: 21 (CDR-L1), 34 (CDR-L2), 53 (CDR-L3), 61 (CDR-H1), 75 (CDR-H2), and 93 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 34 (CDR-L2), 53 (CDR-L3), 101 (CDR-H1), 112 (CDR-H2), and 93 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 35 (CDR-L2), 54 (CDR-L3), 61 (CDR-H1), 76 (CDR-H2), and 94 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 35 (CDR-L2), 54 (CDR-L3), 101 (CDR-H1), 113 (CDR-H2), and 94 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 36 (CDR-L2), 55 (CDR-L3), 61 (CDR-H1), 77 (CDR-H2), and 95 (CDR-H3); and
SEQ ID NOS: 21 (CDR-L1), 36 (CDR-L2), 55 (CDR-L3), 101 (CDR-H1), 114 (CDR-H2), and 95 (CDR-H3); and
detecting binding between the one or more additional scFvs reactive with TAR DNA-binding protein 43 (TDP-43) disease variants, alpha-syn disease variants, or tau disease variants and the biological sample, wherein the detection of binding between the one or more additional scFvs to the biological sample is indicative that the subject has or is likely to develop FTD.

### Claim 4 (depends on 3)

The method of claim 3, wherein the scFv reactive with one or more TDP-43 disease variants has the amino acid sequence set forth in one of SEQ ID NOs: 8-20.

### Claim 5 (depends on 3)

The method of claim 3, wherein the one or more additional scFvs is reactive with one or more alpha-syn disease variants has the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 5.

### Claim 6 (depends on 3)

The method of claim 3, wherein the one or more additional scFvs is reactive with one or more tau disease variants has the amino acid sequence set forth in SEQ ID NO: 6 or SEQ ID NO: 7.

### Claim 7 (depends on 1)

The method of claim 1, wherein the biological sample is a serum sample.

### Claim 8 (depends on 1)

The method of claim 1, wherein the method is performed utilizing an enzyme linked immunosorbent assay (ELISA).

### Claim 9 (depends on 1)

The method of claim 1, further comprising administering a treatment to the subject diagnosed with FTD to treat one or more symptoms associated with FTD.

### Claim 10

A method of monitoring a subject with frontotemporal dementia (FTD), the method comprising:
contacting a first biological sample from a subject diagnosed with FTD with a single-chain variable fragment (scFv) reactive with one or more oligomeric beta amyloid disease variants, wherein the scFv reactive with one or more oligomeric beta amyloid disease variants has a light chain complementary determining region (CDR) and heavy chain CDR combination selected from the group consisting of:
SEQ ID NOS: 21 (CDR-L1), 26 (CDR-L2), 43 (CDR-L3), 62 (CDR-H1), 66 (CDR-H2), and 85 (CDR-H3); and
SEQ ID NOS: 21 (CDR-L1), 27 (CDR-L2), 44 (CDR-L3), 61 (CDR-H1), 67 (CDR-H2), and 85 (CDR-H3);
detecting binding between the one or more scFvs and the first biological sample;
administering a treatment to the subject diagnosed with FTD;
at a desired time, contacting a second biological sample obtained from the subject with one or more scFvs reactive with one or more oligomeric beta amyloid disease variants; and
detecting binding between the one or more scFvs and the second biological sample.

### Claim 11 (depends on 10)

The method of claim 10, wherein the scFv reactive with one or more oligomeric beta amyloid disease variants has the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4.

### Claim 12 (depends on 10)

The method of claim 10, further comprising:
contacting the first biological sample and/or the second biological sample from the subject diagnosed with FTD with one or more additional scFvs reactive with TAR DNA-binding protein 43 (TDP-43) disease variants, alpha-syn disease variants, or tau disease variants, wherein the one or more additional scFvs reactive with TDP-43 disease variants, alpha-syn disease variants, or tau disease variants has a light chain CDR and heavy chain CDR combination or a light chain CDR combination and truncated heavy chain selected from the group consisting of:
SEQ ID NOS: 21 (CDR-L1), 24 (CDR-L2), 41 (CDR-L3), 61 (CDR-H1), 64 (CDR-H2), and 83 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 24 (CDR-L2), 41 (CDR-L3), 101 (CDR-H1), 103 (CDR-H2), and 83 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 25 (CDR-L2), 42 (CDR-L3), 61 (CDR-H1), 65 (CDR-H2), and 84 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 28 (CDR-L2), 45 (CDR-L3), 61 (CDR-H1), 68 (CDR-H2), and 87 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 28 (CDR-L2), 45 (CDR-L3), 101 (CDR-H1), 106 (CDR-H2), and 87 (CDR-H3);
SEQ ID NOS: 22 (CDR-L1), 29 (CDR-L2), 46 (CDR-L3), 61 (CDR-H1), 69 (CDR-H2), and 88 (CDR-H3);
SEQ ID NOS: 22 (CDR-L1), 29 (CDR-L2), 46 (CDR-L3), 101 (CDR-H1), 107 (CDR-H2), and 88 (CDR-H3);
SEQ ID NOS: 23 (CDR-L1), 30 (CDR-L2), 47 (CDR-L3), 63 (CDR-H1), 70 (CDR-H2), and 89 (CDR-H3);
SEQ ID NOS: 23 (CDR-L1), 30 (CDR-L2), 47 (CDR-L3), 102 (CDR-H1), 108 (CDR-H2), and 89 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 32 (CDR-L2), and 49 (CDR-L3);
SEQ ID NOS: 21 (CDR-L1), 27 (CDR-L2), 50 (CDR-L3), 61 (CDR-H1), 72 (CDR-H2), and 91 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 26 (CDR-L2), 51 (CDR-L3), 61 (CDR-H1), 73 (CDR-H2), and 92 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 26 (CDR-L2), 51 (CDR-L3), 101 (CDR-H1), 110 (CDR-H2), and 92 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 33 (CDR-L2), 52 (CDR-L3), 61 (CDR-H1), and 74 (CDR-H2);
SEQ ID NOS: 21 (CDR-L1), 33 (CDR-L2), 52 (CDR-L3), 101 (CDR-H1), and 111 (CDR-H2);
SEQ ID NOS: 21 (CDR-L1), 34 (CDR-L2), 53 (CDR-L3), 61 (CDR-H1), 75 (CDR-H2), and 93 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 34 (CDR-L2), 53 (CDR-L3), 101 (CDR-H1), 112 (CDR-H2), and 93 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 35 (CDR-L2), 54 (CDR-L3), 61 (CDR-H1), 76 (CDR-H2), and 94 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 35 (CDR-L2), 54 (CDR-L3), 101 (CDR-H1), 113 (CDR-H2), and 94 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 36 (CDR-L2), 55 (CDR-L3), 61 (CDR-H1), 77 (CDR-H2), and 95 (CDR-H3); and
SEQ ID NOS: 21 (CDR-L1), 36 (CDR-L2), 55 (CDR-L3), 101 (CDR-H1), 114 (CDR-H2), and 95 (CDR-H3); and
detecting binding between the one or more additional scFvs reactive with TAR DNA-binding protein 43 (TDP-43) disease variants, alpha-syn disease variants, or tau disease variants and the first and/or the second biological sample.

### Claim 13 (depends on 11)

The method of claim 11, wherein the scFv reactive with one or more TDP-43 disease variants has the amino acid sequence set forth in one of SEQ ID NOs: 8-20.

### Claim 14 (depends on 11)

The method of claim 11, wherein the one or more additional scFvs is reactive with one or more alpha-syn disease variants has the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 5.

### Claim 15 (depends on 11)

The method of claim 11, wherein the one or more additional scFvs is reactive with one or more tau disease variants has the amino acid sequence set forth in SEQ ID NO: 6 or SEQ ID NO: 7.

### Claim 16 (depends on 10)

The method of claim 10, wherein the biological sample is a serum sample.

### Claim 17

A kit for detecting frontotemporal dementia (FTD), the kit comprising:
a single-chain variable fragment (scFv) reactive with one or more oligomeric beta amyloid disease variants, wherein the scFv reactive with one or more oligomeric beta amyloid disease variants has a light chain complementary determining region (CDR) and heavy chain CDR combination selected from the group consisting of:
SEQ ID NOS: 21 (CDR-L1), 26 (CDR-L2), 43 (CDR-L3), 62 (CDR-H1), 66 (CDR-H2), and 85 (CDR-H3); and
SEQ ID NOS: 21 (CDR-L1), 27 (CDR-L2), 44 (CDR-L3), 61 (CDR-H1), 67 (CDR-H2), and 85 (CDR-H3);
one or more controls; and
instructions for using the kit.

### Claim 18 (depends on 17)

The kit of claim 17, wherein the scFv reactive with one or more oligomeric beta amyloid disease variants has the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4.

### Claim 19 (depends on 17)

The kit of claim 17, wherein the instructions for using the kit comprise detecting binding between one or more scFvs and a biological sample from a subject, the binding being indicative of the subject having or likely to develop FTD.

### Claim 20 (depends on 17)

The kit of claim 17, further comprising one or more additional scFvs reactive with TAR DNA-binding protein 43 (TDP-43) disease variants, alpha-syn disease variants, or tau disease variants, wherein the one or more additional scFvs reactive with TDP-43 disease variants, alpha-syn disease variants, or tau disease variants has a light chain CDR and heavy chain CDR combination or a light chain CDR combination and truncated heavy chain selected from the group consisting of:
SEQ ID NOS: 21 (CDR-L1), 24 (CDR-L2), 41 (CDR-L3), 61 (CDR-H1), 64 (CDR-H2), and 83 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 24 (CDR-L2), 41 (CDR-L3), 101 (CDR-H1), 103 (CDR-H2), and 83 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 25 (CDR-L2), 42 (CDR-L3), 61 (CDR-H1), 65 (CDR-H2), and 84 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 28 (CDR-L2), 45 (CDR-L3), 61 (CDR-H1), 68 (CDR-H2), and 87 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 28 (CDR-L2), 45 (CDR-L3), 101 (CDR-H1), 106 (CDR-H2), and 87 (CDR-H3);
SEQ ID NOS: 22 (CDR-L1), 29 (CDR-L2), 46 (CDR-L3), 61 (CDR-H1), 69 (CDR-H2), and 88 (CDR-H3);
SEQ ID NOS: 22 (CDR-L1), 29 (CDR-L2), 46 (CDR-L3), 101 (CDR-H1), 107 (CDR-H2), and 88 (CDR-H3);
SEQ ID NOS: 23 (CDR-L1), 30 (CDR-L2), 47 (CDR-L3), 63 (CDR-H1), 70 (CDR-H2), and 89 (CDR-H3);
SEQ ID NOS: 23 (CDR-L1), 30 (CDR-L2), 47 (CDR-L3), 102 (CDR-H1), 108 (CDR-H2), and 89 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 32 (CDR-L2), and 49 (CDR-L3);
SEQ ID NOS: 21 (CDR-L1), 27 (CDR-L2), 50 (CDR-L3), 61 (CDR-H1), 72 (CDR-H2), and 91 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 26 (CDR-L2), 51 (CDR-L3), 61 (CDR-H1), 73 (CDR-H2), and 92 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 26 (CDR-L2), 51 (CDR-L3), 101 (CDR-H1), 110 (CDR-H2), and 92 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 33 (CDR-L2), 52 (CDR-L3), 61 (CDR-H1), and 74 (CDR-H2);
SEQ ID NOS: 21 (CDR-L1), 33 (CDR-L2), 52 (CDR-L3), 101 (CDR-H1), and 111 (CDR-H2);
SEQ ID NOS: 21 (CDR-L1), 34 (CDR-L2), 53 (CDR-L3), 61 (CDR-H1), 75 (CDR-H2), and 93 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 34 (CDR-L2), 53 (CDR-L3), 101 (CDR-H1), 112 (CDR-H2), and 93 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 35 (CDR-L2), 54 (CDR-L3), 61 (CDR-H1), 76 (CDR-H2), and 94 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 35 (CDR-L2), 54 (CDR-L3), 101 (CDR-H1), 113 (CDR-H2), and 94 (CDR-H3);
SEQ ID NOS: 21 (CDR-L1), 36 (CDR-L2), 55 (CDR-L3), 61 (CDR-H1), 77 (CDR-H2), and 95 (CDR-H3); and
SEQ ID NOS: 21 (CDR-L1), 36 (CDR-L2), 55 (CDR-L3), 101 (CDR-H1), 114 (CDR-H2), and 95 (CDR-H3).
